Huons Biopharma's Hutox Becomes Seventh Botulinum Toxin Approved in China Following NMPA Authorization
Key Insights
Huons Biopharma (search)'s Chinese partner iMaker Technology (search) received NMPA approval for Hutox, a type A botulinum toxin product, marking the second Korean company to enter China's botulinum toxin market.
The 100-unit Hutox injection completed Phase 3 clinical trials in China for treating moderate to severe facial wrinkles (search) and received commercialization approval approximately 1 year and 7 months after NDA submission.
Hutox becomes the seventh botulinum toxin product commercialized in China, joining established competitors including AbbVie (search)'s Botox, Hugel (search)'s Letybo (search), and Ipsen's Dysport.
Huons Biopharma (search) announced that its Chinese partner iMaker Technology (search) has obtained product approval for the type A botulinum toxin product 'Hutox' from China's National Medical Products Administration (NMPA). This milestone represents the second case of a Korean company successfully receiving marketing authorization in China for type A botulinum toxin, positioning Huons Biopharma for significant market expansion in the world's second-largest pharmaceutical market.
Regulatory Approval and Clinical Development
The 100-unit Hutox injection completed Phase 3 clinical trials in China targeting the improvement of moderate to severe glabellar lines (search). After submitting the New Drug Application (NDA) in June 2024, the product achieved commercialization approval in approximately 1 year and 7 months. The Center for Drug Evaluation (CDE) under the NMPA completed comprehensive technical reviews across four critical categories: clinical, pharmaceutical, statistical, and regulatory suitability before issuing the final drug registration license to iMaker.
iMaker Technology (search) secured exclusive import and distribution rights for Hutox in China, including Macau and Hong Kong, from Huons Biopharma (search) in 2022. Following this partnership agreement, the company conducted local clinical trials before applying for product approval in 2024.
Product Characteristics and Manufacturing Standards
Hutox is a cosmetic and therapeutic drug containing botulinum toxin type A as its main ingredient, primarily used to improve wrinkles around the eyes and glabellar lines (search). The product is characterized by high-purity botulinum toxin type A manufacturing and adheres to quality control standards according to the China Pharmacopoeia. Huons Biopharma (search), spun off from Huons Global in 2021, specializes in botulinum toxin development and serves as the parent company's dedicated biologics division.
Competitive Landscape in China
With this approval, Hutox becomes the seventh commercialized botulinum toxin product in the Chinese market. The competitive landscape includes established players such as AbbVie (search)'s Botox, China's Lanzhou Bio's Hengli, France's Ipsen's Dysport, Korea's Hugel (search)'s Letybo (search), Germany's Merz's Xeomin, and Israel's Cisram Medical Technology's Daxify. Additionally, more than 10 Chinese and global companies are currently in clinical development or regulatory approval stages for similar products.
Market Launch Strategy and Global Expansion
iMaker plans to commercialize Hutox by leveraging its established distribution network throughout China. The company's existing infrastructure includes its own filler production plant and research institute, which should enable rapid market launch and establishment of a stable supply system.
Huons Biopharma (search) has already obtained marketing authorization for Hutox in 15 countries and continues export operations. The company is pursuing additional national approvals with focus on Latin America, Southeast Asia, and the Middle East markets.
Executive Commentary and Future Outlook
Kim Young-mok, CEO of Huons Biopharma (search), stated, "I'm happy to deliver meaningful results of entering the Chinese market in the new year. If we've been in the preparation stage for exports, we're now in the stage of producing tangible results, so we look forward to expanding the global market for Huons Biopharma."
Kim emphasized the company's strengthening regulatory capabilities, noting, "As understanding and response capabilities to the global regulatory environment are strengthened, data submission and technical response tailored to regulatory requirements by country are being carried out stably. Hutox's global position will be strengthened depending on additional national permits and supply expansion in the future."